

Guselkumab		
<i>Psoriatic arthritis, plaque psoriasis</i>		
Poster/ Presentation #	Abstract Name	Presentation Time
AB0426	Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post hoc Analysis of 4 Phase 3, Randomized, Controlled Studies	Book only
AB0431	Musculoskeletal Ultrasound Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis	Book only
<i>Psoriatic arthritis</i>		
AB0401	Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies	Book only
POS0254	A Novel Composite Endpoint Including Low Peripheral Joint Disease Activity State and Clear/Almost Clear Skin in Patients with Active Psoriatic Arthritis: Post Hoc Analyses of 2 Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies	Poster tour Friday, June 14 9:30-10:30 CEST
AB0472	Efficacy of Guselkumab in Bionative Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study	Book only
POS0249	Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-naïve Patients with PsA with MRI-confirmed Axial Involvement	Poster tour Friday, June 14 9:30-10:30 CEST
AB0438	Baseline Characteristics of Real-World Psoriatic Arthritis Patients Treated with Guselkumab or IL-17 Inhibitors: Results from the Ongoing Multinational PsABIOnd Study	Book only
POS0943	Guselkumab Provides Durable Improvements in Pain Among Patients with Psoriatic Arthritis and an Inadequate Response to TNFi: COSMOS Phase 3b Trial	Poster view Friday, June 14 9:30-10:30 CEST
POS0322	Guselkumab Binding to CD64+ IL-23-Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling	Poster tour Friday, June 14 12:00-13:30 CEST
POS0966	Psoriatic Arthritis Patient Profiles are Different Between Randomised Controlled Trials of Biological Disease-Modifying Antirheumatic Drugs and a Real-World Study Over the Same Timeframe (PsABio) – a Literature Review with Meta-Analysis	Poster view Friday, June 14 9:30 - 10:30 CEST
AB0410	Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous TNF Inhibitors	Book only
POS0984	Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors	Poster view Friday, June 14 9:30-10:30 CEST
AB1668-PARE	Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry	Book only
POS0983	Pooled Analysis of Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies to Longitudinally Evaluate the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Guselkumab Treatment	Poster view Friday, June 14 9:30-10:30 CEST
AB0491	Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active Psoriatic Arthritis	Book only
AB0480	Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc	Book only

	Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients	
AB0412	Guselkumab Provides Clinically Meaningful Improvements in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis who are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled study (COSMOS)	Book only
<i>Plaque psoriasis</i>		
POS0942	VISIBLE: Clearance and Symptom Improvement with Guselkumab at Week 16 in Skin of Color Participants with Moderate-to-Severe Plaque Psoriasis	Poster view Friday, June 14 9:30-10:30 CEST
<i>Ulcerative colitis</i>		
AB1410	Early Symptomatic Improvement with Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Induction Study	Book only
AB1415	Guselkumab Induction Restores Intestinal Immune Homeostasis and Promotes Epithelial Repair in Moderately to Severely Active Ulcerative Colitis	Book only
AB1381	Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing that is Sustained Through Guselkumab Maintenance Therapy	Book only
Nipocalimab		
<i>Sjögren's disease</i>		
LBA0010	Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren's disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)	Oral abstract session Saturday, June 15 9:00-10:00 CEST
POS1243	Association of Sjögren's Disease Activity (ClinESSDAI) and Symptom Burden (ESSPRI) with Patient-Reported Outcome Measures	Poster view Friday, June 14 14:45-15:45 CEST
POS1236	Sjögren's Disease Activity and Clinical Characteristics of Patients with Seropositive and Seronegative Anti-SSA/Ro and Anti-SSB/La Antibody Test Results	Poster view Friday, June 14 14:45-15:45 CEST
<i>Lupus</i>		
POS0114	Lupus Nephritis and Response to Treatment in Latin America	Poster tour Thursday, June 13 9:30-10:30 CEST
POS0741	Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort	Poster view Thursday, June 13 12:00-13:30 CEST
POS1016	The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort	Poster view Friday, June 14 9:30-10:30 CEST
AB1553-HPR	Baseline Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network	Book only
<i>Idiopathic inflammatory myopathies</i>		
AB0250	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies (SPIREA): Study Design	Book only
POS1280	Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis	Poster view Friday, June 14 14:45-15:45 CEST